Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) EBITDA: 2020-2025

Historic EBITDA for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -$61.2 million.

  • 4D Molecular Therapeutics' EBITDA fell 19.66% to -$61.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$230.4 million, marking a year-over-year decrease of 36.82%. This contributed to the annual value of -$187.8 million for FY2024, which is 66.43% down from last year.
  • 4D Molecular Therapeutics' EBITDA amounted to -$61.2 million in Q3 2025, which was down 2.91% from -$59.5 million recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' EBITDA ranged from a high of -$7.6 million in Q2 2021 and a low of -$61.2 million during Q3 2025.
  • Over the past 3 years, 4D Molecular Therapeutics' median EBITDA value was -$42.5 million (recorded in 2024), while the average stood at -$43.2 million.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' EBITDA soared by 49.86% in 2021, and later slumped by 274.22% in 2022.
  • Over the past 5 years, 4D Molecular Therapeutics' EBITDA (Quarterly) stood at -$24.8 million in 2021, then fell by 15.97% to -$28.7 million in 2022, then declined by 27.62% to -$36.7 million in 2023, then slumped by 53.11% to -$56.1 million in 2024, then dropped by 19.66% to -$61.2 million in 2025.
  • Its EBITDA was -$61.2 million in Q3 2025, compared to -$59.5 million in Q2 2025 and -$53.6 million in Q1 2025.